R
Robert O. Friedel
Researcher at University of Washington
Publications - 12
Citations - 563
Robert O. Friedel is an academic researcher from University of Washington. The author has contributed to research in topics: Desipramine & Borderline personality disorder. The author has an hindex of 10, co-authored 12 publications receiving 563 citations.
Papers
More filters
Journal ArticleDOI
Prediction of tricyclic antidepressant response: a critical review.
TL;DR: Pretreatment urinary 3-methoxy-4-hydroxyphenylglycol levels may some day be useful in predicting to which of these two tricyclic antidepressants a patient will respond.
Journal ArticleDOI
Low-Dose Neuroleptic Regimens in the Treatment of Borderline Patients
TL;DR: Five case histories of patients with conditions diagnosed and treated in this manner are presented, followed by a discussion of the implications of this approach in terms of clarifying the nosologic issues that have arisen around the "borderline" concept.
Journal ArticleDOI
Electrocardiogram changes and plasma desipramine levels during treatment of depression.
TL;DR: Twenty‐six symptomatic subjects who met research diagnostic criteria for major affective disorder and were free of cardiovascular disease were treated with a fixed dosage schedule of desipramine to a maximum of 200 mg/day with no clinically significant ECG alterations or cardiovascular adverse effects.
Journal ArticleDOI
Analysis of Tricyclic Antidepressants in Human Plasma by GLC–Chemical-Ionization Mass Spectrometry with Selected Ion Monitoring
Rand Jenkins,Robert O. Friedel +1 more
TL;DR: A method is described for the analysis of amitriptyline, doxepin, imipramine, nortriptylines, desmethyldoxepins, desipramines, and protripty lines in human plasma utlizing GLC-chemical-ionization mass spectrometry with selected ion monitoring.
Journal ArticleDOI
Urinary MHPG excretion and treatment with desipramine or amitriptyline: prediction of response, effect of treatment, and methodological hazards.
Richard C. Veith,Robert J. Bielski,Valerie L. Bloom,Jan Fawcett,Nedathur Narasimhachari,Robert O. Friedel +5 more
TL;DR: Among patients within the postulated optimal desipramine plasma level range and patients with plasma amitriptyline plus nortriptylines levels > 70 ng/ml, high pretment MHPG excretion predicted therapeutic response and response was accompanied by a reduction in MHPGexcretion.